The meeting introduced Ultra Botanica’s oncology heat maps and the goal that clinicians be able to use the mapping tool with a presenting patient by the end of the session. Adam Payne, CEO and founder, outlined the scientific rationale and development history, describing the OncoAdjunct reference that organizes twenty cellular pathways into five functional pillars and the protosorb delivery technology designed to keep bioactive compounds amorphous for improved gut uptake and intracellular delivery.
Discussion progressed through pathway-specific product rationales in sequence: a curcumin-based formulation paired with quercetin and boswellic acid for inflammation, proliferation, and apoptosis; a fisetin-centered blend with EGCG, resveratrol, and high‑purity beta‑glucan aimed at senescence and autophagy; and a berberine plus fermented wheat germ extract approach targeting aerobic glycolysis and AMPK-related metabolism. The team reviewed four years of in‑house lab work and an academic collaboration, presented meta‑analytic observations about conserved pathway dysregulation across diagnoses and possible links to tumor-associated microbiomes, and demonstrated map interpretation using digestive cancers (rectal adenocarcinoma) to prioritize interventions. The group also confirmed imminent beta testing of a software version with literature‑backed calculations and micromolar simulation, collected early clinician feedback, and committed to sending the recording, transcript, a temporary free‑shipping code, and email follow-up about next steps and monthly roundtables.